pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
HUMIRA · news · pharmadog
← back to HUMIRA
News mentioning HUMIRA
19
stories
3d
Deaths, failed trials and other recent setbacks in the autoimmune space
biospace
15d
AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
fiercebiotech
20d
AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals
biospace
22d
5 new drug launches that defied industry expectations
biospace
28d
AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
biospace
28d
Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
biospace
28d
Celltrion picks up another Kaigene autoimmune antibody for up to $580.5M
fiercebiotech
29d
Roivant, continuing ascent, claims another victory for rare disease drug
biopharma dive
29d
STAT+: Roivant says closely watched immune drug succeeded in new eye disease
stat
Oct 19, 26
As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
biospace
Oct 2, 26
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
Oct 1, 26
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
biospace
Sep 28, 26
6 immunology targets to sustain a mammoth I&I market
biospace
Sep 10, 26
Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'
biospace
Aug 10, 26
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
Jul 31, 26
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
Jun 18, 26
cAMPfield lands $180M to build gut disease drug
biopharma dive
Jun 18, 26
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
biopharma dive
Apr 25, 26
Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
stat